<HashMap><database>biostudies-literature</database><scores/><additional><submitter>van Tienhoven R</submitter><funding>The Wanek Family Project for Type 1 Diabetes</funding><funding>Leona M. and Harry B. Helmsley Charitable Trust</funding><funding>Stichting Diabetes Onderzoek Nederland</funding><funding>IMI2-JU</funding><funding>NIDDK NIH HHS</funding><funding>Juvenile Diabetes Research Foundation</funding><funding>ZonMw</funding><funding>Diabetes Fonds</funding><pagination>884-896</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10036285</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>66(5)</volume><pubmed_abstract>&lt;h4>Aims/hypothesis&lt;/h4>Transcriptome analyses revealed insulin-gene-derived transcripts in non-beta endocrine islet cells. We studied alternative splicing of human INS mRNA in pancreatic islets.&lt;h4>Methods&lt;/h4>Alternative splicing of insulin pre-mRNA was determined by PCR analysis performed on human islet RNA and single-cell RNA-seq analysis. Antisera were generated to detect insulin variants in human pancreatic tissue using immunohistochemistry, electron microscopy and single-cell western blot to confirm the expression of insulin variants. Cytotoxic T lymphocyte (CTL) activation was determined by MIP-1β release.&lt;h4>Results&lt;/h4>We identified an alternatively spliced INS product. This variant encodes the complete insulin signal peptide and B chain and an alternative C-terminus that largely</pubmed_abstract><journal>Diabetologia</journal><pubmed_title>Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cells.</pubmed_title><pmcid>PMC10036285</pmcid><funding_grant_id>U24 DK098085</funding_grant_id><funding_grant_id>G-2108-04793</funding_grant_id><funding_grant_id>5-SRA-2018-557-Q-R</funding_grant_id><funding_grant_id>91111.006</funding_grant_id><pubmed_authors>Kracht MJL</pubmed_authors><pubmed_authors>Thomaidou S</pubmed_authors><pubmed_authors>Carlotti F</pubmed_authors><pubmed_authors>Riojas JPR</pubmed_authors><pubmed_authors>de Koning EJP</pubmed_authors><pubmed_authors>Roep BO</pubmed_authors><pubmed_authors>van der Slik AR</pubmed_authors><pubmed_authors>Giepmans BNG</pubmed_authors><pubmed_authors>Nelson MS</pubmed_authors><pubmed_authors>Zaldumbide A</pubmed_authors><pubmed_authors>van Tienhoven R</pubmed_authors><pubmed_authors>Hoeben RC</pubmed_authors><pubmed_authors>Wolters AHG</pubmed_authors></additional><is_claimable>false</is_claimable><name>Presence of immunogenic alternatively spliced insulin gene product in human pancreatic delta cells.</name><description>&lt;h4>Aims/hypothesis&lt;/h4>Transcriptome analyses revealed insulin-gene-derived transcripts in non-beta endocrine islet cells. We studied alternative splicing of human INS mRNA in pancreatic islets.&lt;h4>Methods&lt;/h4>Alternative splicing of insulin pre-mRNA was determined by PCR analysis performed on human islet RNA and single-cell RNA-seq analysis. Antisera were generated to detect insulin variants in human pancreatic tissue using immunohistochemistry, electron microscopy and single-cell western blot to confirm the expression of insulin variants. Cytotoxic T lymphocyte (CTL) activation was determined by MIP-1β release.&lt;h4>Results&lt;/h4>We identified an alternatively spliced INS product. This variant encodes the complete insulin signal peptide and B chain and an alternative C-terminus that largely</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2026-07-14T19:09:03.973Z</modification><creation>2025-02-19T00:49:41.469Z</creation></dates><accession>S-EPMC10036285</accession><cross_references><pubmed>36884057</pubmed><doi>10.1007/s00125-023-05882-y</doi></cross_references></HashMap>